AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38937798 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Citizen Assistance for Social Participation (APIC); weekly 3-h personalized stimulation sessions given by a trained volunteer over a 12-month period
Number of subjects: 14
Study 38937798 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted intervention for remote delivery via telephone or videoconferencing due to COVID-19 restrictions
Number of subjects: 14
Study 38937803 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical CD34+ enriched and CD45RA-depleted hematopoietic progenitor cell grafts followed by NK-cell infusion
Number of subjects: 72
Study 38937824 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality cue-exposure therapy (VRCET) plus memory-focused cognitive therapy (MFCT)
Number of subjects: 54
Study 38937824 — intervention group
Group type: COMPARATOR
Intervention: Picture-based cue-exposure therapy (PCET)
Number of subjects: 54
Study 38937824 — intervention group
Group type: EXPERIMENTAL
Intervention: VRCET
Number of subjects: 54
Study 38937824 — intervention group
Group type: COMPARATOR
Intervention: PCET
Number of subjects: 54
Study 38937954 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal anaesthesia and analgesia with opioids
Number of subjects: 0
Study 38937954 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anaesthesia
Number of subjects: 0
Study 38937954 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (for both pain-sensitive and pain-tolerant groups)
Number of subjects: 0
Study 38937954 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 38938171 — intervention group
Group type: EXPERIMENTAL
Intervention: Napping on school days
Number of subjects: 153
Study 38938171 — intervention group
Group type: EXPERIMENTAL
Intervention: Napping on weekends
Number of subjects: 153
Study 38938171 — intervention group
Group type: EXPERIMENTAL
Intervention: Early wake times
Number of subjects: 153
Study 38938171 — intervention group
Group type: EXPERIMENTAL
Intervention: Long and late naps on school days
Number of subjects: 153
Study 38938171 — intervention group
Group type: EXPERIMENTAL
Intervention: Napping duration and timing
Number of subjects: 153
Study 38938171 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal sleep duration
Number of subjects: 153
Study 38938363 — intervention group
Group type: EXPERIMENTAL
Intervention: AliveCor KardiaMobile 1L ECG
Number of subjects: 14230
Study 38938387 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered SAGE used during PCP visits
Number of subjects: 300
Study 38938387 — intervention group
Group type: COMPARATOR
Intervention: Control group (PCP visits without SAGE)
Number of subjects: 300
Study 38938412 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention test (Continuous Performance Task)
Number of subjects: 20
Study 38938519 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk from GDM+ women
Number of subjects: 53
Study 38938519 — intervention group
Group type: COMPARATOR
Intervention: Human milk from GDM- women
Number of subjects: 53
Study 38938704 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized use of accepted criteria for PAH diagnosis with pop-up reminders during data entry.
Number of subjects: 217
Study 38938704 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiogram (TTE) assessment.
Number of subjects: 217
Study 38938704 — intervention group
Group type: EXPERIMENTAL
Intervention: Right heart catheterization (RHC).
Number of subjects: 217
Study 38938704 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured protocol for screening.
Number of subjects: 217
Study 38938712 — intervention group
Group type: EXPERIMENTAL
Intervention: K-Clip system
Number of subjects: 39
Study 38939193 — intervention group
Group type: EXPERIMENTAL
Intervention: taTME
Number of subjects: 0
Study 38939193 — intervention group
Group type: COMPARATOR
Intervention: laTME
Number of subjects: 0
Study 38939366 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet for 4 weeks
Number of subjects: 155
Study 38939366 — intervention group
Group type: EXPERIMENTAL
Intervention: Starch- and sucrose-reduced diet (SSRD) for 4 weeks
Number of subjects: 155
Study 38939381 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography with fractional flow reserve
Number of subjects: 50
Study 38939389 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1455
Study 38939389 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K Antagonist (VKA)
Number of subjects: 1455
Study 38939428 — intervention group
Group type: EXPERIMENTAL
Intervention: CR intervention (multidisciplinary model of cardiac rehabilitation including guideline-directed management of cardiovascular risk factors, dietary counselling, and supervised exercise for 52 weeks)
Number of subjects: 74
Study 38939428 — intervention group
Group type: EXPERIMENTAL
Intervention: CR intervention
Number of subjects: 74
Study 38939428 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 74
Study 38939456 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis (80 mg or 20 mg)
Number of subjects: 441
Study 38939456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study 38939480 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended dose edoxaban
Number of subjects: 176
Study 38939496 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg/d)
Number of subjects: 2814
Study 38939496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2814
Study 38939518 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-PD1 treatment
Number of subjects: 0
Study 38939580 — intervention group
Group type: EXPERIMENTAL
Intervention: Duke Activity Status Index (DASI)
Number of subjects: 1019
Study 38939580 — intervention group
Group type: COMPARATOR
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 1019
Study 38939586 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment elevation myocardial infarction (STEMI)
Number of subjects: 87812
Study 38939586 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ST-segment elevation ACS (NSTE-ACS)
Number of subjects: 87812
Study 38939629 — intervention group
Group type: EXPERIMENTAL
Intervention: Organized treatment pathway
Number of subjects: 500
Study 38939629 — intervention group
Group type: COMPARATOR
Intervention: Routine-care approach (Control)
Number of subjects: 500
Study 38939651 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital multicomponent exercise program for 3, 4, or 5-7 consecutive days
Number of subjects: 570
Study 38939651 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day exercise program
Number of subjects: 570
Study 38939651 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-7 day exercise program
Number of subjects: 570
Study 38939654 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased left atrial (LA) stiffness
Number of subjects: 150
Study 38939654 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 150
Study 38939654 — intervention group
Group type: EXPERIMENTAL
Intervention: LA myopathy with increased LA stiffness and impaired LA mechanics
Number of subjects: 150
Study 38939657 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 5670
Study 38939657 — intervention group
Group type: COMPARATOR
Intervention: Males
Number of subjects: 5670
Study 38939657 — intervention group
Group type: EXPERIMENTAL
Intervention: Females under 55 years
Number of subjects: 5670
Study 38939657 — intervention group
Group type: EXPERIMENTAL
Intervention: Females over 55 years
Number of subjects: 5670
Study 38939675 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 9054
Study 38939799 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPS (noninvasive programmed ventricular stimulation)
Number of subjects: 41
Study 38939828 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day plus cholecalciferol 800 IU/day (RalD)
Number of subjects: 112
Study 38939828 — intervention group
Group type: COMPARATOR
Intervention: Cholecalciferol 800 IU/day (VitD)
Number of subjects: 112
Study 38940186 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick bedside cTn test by ambulance paramedics using a point-of-care device with the HEART-score
Number of subjects: 0
Study 38940186 — intervention group
Group type: COMPARATOR
Intervention: Detailed hospital cTn test by doctors with the HEART-score
Number of subjects: 0
Study 38940282 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide 240 mg/day
Number of subjects: 1052
Study 38940282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1052
Study 38940297 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated valve technology
Number of subjects: 2913
Study 38940297 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-thrombogenic surface modification
Number of subjects: 2913
Study 38940297 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial impregnation
Number of subjects: 2913
Study 38940373 — intervention group
Group type: EXPERIMENTAL
Intervention: Oregovomab plus non-platinum-based chemotherapy (pegylated liposomal doxorubicin or paclitaxel)
Number of subjects: 0
Study 38940373 — intervention group
Group type: COMPARATOR
Intervention: Non-platinum-based chemotherapy (pegylated liposomal doxorubicin or paclitaxel)
Number of subjects: 0
Study 38940374 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective Visual Vertical (SVV)
Number of subjects: 60
Study 38940374 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective Haptic Vertical (SHV)
Number of subjects: 60
Study 38940374 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 60
Study 38940374 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 60
Study 38940374 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting positions
Number of subjects: 60
Study 38940435 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg weekly
Number of subjects: 0
Study 38940435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38940494 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme for healthcare professionals (bespoke interactive online learning and reinforcement activities)
Number of subjects: 1732
Study 38940494 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme for healthcare professionals
Number of subjects: 1732
Study 38940494 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants
Number of subjects: 1732
Study 38940494 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug therapy
Number of subjects: 1732
Study 38940494 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled for future cardioversion or ablation
Number of subjects: 1732
Study 38940656 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorylated plasma Tau217 ratio (pTau217R)
Number of subjects: 904
Study 38940656 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pTau217R and plasma Aβ42/Aβ40
Number of subjects: 904
Study 38940656 — intervention group
Group type: COMPARATOR
Intervention: Aβ42/Aβ40 alone
Number of subjects: 904
Study 38940695 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management (reconstruction)
Number of subjects: 316
Study 38940695 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical management (rehabilitation)
Number of subjects: 316
Study 38940733 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation Treatment with a Home-Use Device
Number of subjects: 0
Study 38940733 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38940865 — intervention group
Group type: EXPERIMENTAL
Intervention: JN.1 infection
Number of subjects: 182
Study 38940865 — intervention group
Group type: COMPARATOR
Intervention: XBB infection
Number of subjects: 182
Study 38940898 — intervention group
Group type: EXPERIMENTAL
Intervention: GACMS
Number of subjects: 25
Study 38940898 — intervention group
Group type: EXPERIMENTAL
Intervention: RRM
Number of subjects: 25
Study 38940898 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated breast cancer risk
Number of subjects: 25
Study 38940898 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated breast cancer risk
Number of subjects: 25
Study 38940981 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian function recovery (OFR) in patients with CIOFF receiving anastrozole treatment.
Number of subjects: 656
Study 38941062 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-on-polyethylene (MoP) arthroplasty implants
Number of subjects: 25
Study 38941062 — intervention group
Group type: COMPARATOR
Intervention: Control group (deceased subjects without prostheses)
Number of subjects: 25
Study 38941062 — intervention group
Group type: EXPERIMENTAL
Intervention: MoP arthroplasty implants
Number of subjects: 25
Study 38941068 — intervention group
Group type: EXPERIMENTAL
Intervention: VOWST oral spores (VOS)
Number of subjects: 349
Study 38941068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study 38941132 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute stepper test (6MST) conducted under direct supervision
Number of subjects: 82
Study 38941132 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute stepper test (6MST) conducted under remote supervision
Number of subjects: 82
Study 38941132 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent validity of 6MST compared to CPET and 6MWT
Number of subjects: 82
Study 38941132 — intervention group
Group type: COMPARATOR
Intervention: 6-minute walk test (6MWT)
Number of subjects: 82
Study 38941132 — intervention group
Group type: COMPARATOR
Intervention: Maximal cardiopulmonary exercise testing (CPET)
Number of subjects: 82
Study 38941145 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based PA intervention (WI) program
Number of subjects: 196
Study 38941145 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based PA intervention (WI) program with Just-in-Time Adaptive Intervention (WI+JITAI)
Number of subjects: 196
Study 38941145 — intervention group
Group type: COMPARATOR
Intervention: Control group (WI)
Number of subjects: 196
Study 38941148 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient portal intervention
Number of subjects: 433
Study 38941148 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 433
Study 38941376 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Raftlin levels in axSpA patients
Number of subjects: 120
Study 38941376 — intervention group
Group type: COMPARATOR
Intervention: Serum Raftlin levels in PsA patients
Number of subjects: 120
Study 38941376 — intervention group
Group type: COMPARATOR
Intervention: Serum Raftlin levels in control group
Number of subjects: 120
Study 38941376 — intervention group
Group type: EXPERIMENTAL
Intervention: Raftlin level ≥ 6.31 ng/mL
Number of subjects: 120
Study 38941376 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Raftlin levels with disease activity measures in axSpA patients
Number of subjects: 120
Study 38941511 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 11040
Study 38941593 — intervention group
Group type: EXPERIMENTAL
Intervention: KAD patients with HIV
Number of subjects: 0
Study 38941593 — intervention group
Group type: COMPARATOR
Intervention: KICS and MCD
Number of subjects: 0
Study 38941593 — intervention group
Group type: COMPARATOR
Intervention: PEL
Number of subjects: 0
Study 38941593 — intervention group
Group type: EXPERIMENTAL
Intervention: KAD patients
Number of subjects: 0
Study 38941599 — intervention group
Group type: EXPERIMENTAL
Intervention: Syalox 300 Plus (high-molecular-weight hyaluronic acid) administered orally for 8 weeks.
Number of subjects: 8
Study 38941601 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-BP intervention
Number of subjects: 162
Study 38941601 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care control
Number of subjects: 162
Study 38941963 — intervention group
Group type: EXPERIMENTAL
Intervention: SLN ultrastaging
Number of subjects: 733
Study 38941963 — intervention group
Group type: EXPERIMENTAL
Intervention: Examination of four levels from paraffin blocks
Number of subjects: 733
Study 38942046 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus surgery
Number of subjects: 819
Study 38942046 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 819
Study 38942047 — intervention group
Group type: EXPERIMENTAL
Intervention: Namilumab 150 mg subcutaneously at weeks 0, 2, 6, and 10
Number of subjects: 42
Study 38942047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 38942047 — intervention group
Group type: EXPERIMENTAL
Intervention: Namilumab 150 mg
Number of subjects: 42
Study 38942114 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated Lp(a) (≥150 nmol/L)
Number of subjects: 446
Study 38942114 — intervention group
Group type: COMPARATOR
Intervention: Normal Lp(a) and OxPL concentrations
Number of subjects: 446
Study 38942114 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of OxPL-apoB and OxPL-apo(a) to Lp(a)
Number of subjects: 446
Study 38942209 — intervention group
Group type: COMPARATOR
Intervention: Cariprazine 1.5 mg/d
Number of subjects: 0
Study 38942209 — intervention group
Group type: COMPARATOR
Intervention: Cariprazine 3-12 mg/d
Number of subjects: 0
Study 38942591 — intervention group
Group type: EXPERIMENTAL
Intervention: MIST continuation group (n=25)
Number of subjects: 52
Study 38942591 — intervention group
Group type: COMPARATOR
Intervention: MIST discontinuation group (n=27)
Number of subjects: 52
Study 38942591 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 52
Study 38942591 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with anti-dsDNA IgE levels above vs below 1.9 arbitrary units
Number of subjects: 52
Study 38942592 — intervention group
Group type: EXPERIMENTAL
Intervention: Nipocalimab (15 mg/kg intravenously every 2 weeks)
Number of subjects: 53
Study 38942592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 38942592 — intervention group
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Number of subjects: 53
Study 38942601 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) exposure in early pregnancy
Number of subjects: 100
Study 38942693 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc 150 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks
Number of subjects: 40
Study 38942693 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc 250 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks
Number of subjects: 40
Study 38942993 — intervention group
Group type: EXPERIMENTAL
Intervention: Finotonlimab plus cisplatin plus 5-fluorouracil (C5F)
Number of subjects: 370
Study 38942994 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV gene therapy (AP4M1 gene) administered intrathecally
Number of subjects: 1
Study 38942995 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib and nivolumab with CBM588
Number of subjects: 30
Study 38942995 — intervention group
Group type: COMPARATOR
Intervention: Cabozantinib and nivolumab without CBM588 (control)
Number of subjects: 30
Study 38942995 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib and nivolumab with or without CBM588
Number of subjects: 30
Study 38943014 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized SMAs (set content delivered by a health educator)
Number of subjects: 1060
Study 38943014 — intervention group
Group type: COMPARATOR
Intervention: Patient-driven SMAs (patient-selected topic order delivered by health educators, BHPs, and peer mentors)
Number of subjects: 1060
Study 38943014 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized SMAs
Number of subjects: 1060
Study 38943053 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program combining three nutritional workshops and 12 weekly physical activity sessions.
Number of subjects: 187
Study 38943053 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular participation in the program.
Number of subjects: 187
Study 38943053 — intervention group
Group type: COMPARATOR
Intervention: Non-participants in the program.
Number of subjects: 187
Study 38943063 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of CEBA profiles through neuropsychological assessment tests and questionnaires.
Number of subjects: 300
Study 38943063 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative evaluation of treatment suitability for CEBA profiles in a small group of PwMS.
Number of subjects: 300
Study 38943136 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal dental anxiety (assessed using the Modified Dental Anxiety Scale - MDAS)
Number of subjects: 305
Study 38943136 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's dental anxiety (assessed using the Venham Picture Test - VPT)
Number of subjects: 305
Study 38943136 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal dental anxiety
Number of subjects: 305
Study 38943136 — intervention group
Group type: COMPARATOR
Intervention: Children aged 4-7
Number of subjects: 305
Study 38943136 — intervention group
Group type: EXPERIMENTAL
Intervention: Children aged 8-12
Number of subjects: 305
Study 38943155 — intervention group
Group type: COMPARATOR
Intervention: α-cypermethrin only LLIN
Number of subjects: 0
Study 38943155 — intervention group
Group type: COMPARATOR
Intervention: pyriproxyfen and α-cypermethrin (PPF-PY) LLIN
Number of subjects: 0
Study 38943155 — intervention group
Group type: COMPARATOR
Intervention: chlorfenapyr and α-cypermethrin (chlorfenapyr-PY) LLIN
Number of subjects: 0
Study 38943155 — intervention group
Group type: COMPARATOR
Intervention: piperonyl butoxide and permethrin (PBO-PY) LLIN
Number of subjects: 0
Study 38943155 — intervention group
Group type: EXPERIMENTAL
Intervention: Good condition nets vs too-torn nets
Number of subjects: 0
Study 38943155 — intervention group
Group type: COMPARATOR
Intervention: too-torn PBO-PY LLIN vs intact PY-only LLIN
Number of subjects: 0
Study 38943155 — intervention group
Group type: COMPARATOR
Intervention: too-torn chlorfenapyr-PY LLIN vs intact PY-only LLIN
Number of subjects: 0
Study 38943155 — intervention group
Group type: COMPARATOR
Intervention: intact chlorfenapyr-PY LLIN vs intact PY LLIN (Year 2)
Number of subjects: 0
Study 38943163 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline recommendations for pre-operative examinations
Number of subjects: 2003
Study 38943163 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA score
Number of subjects: 2003